Pilot & Feasibility Program

The Center for American Indian and Alaska Native Diabetes Translation Research (CAIANDTR) seeks to translate research of proven efficacy into clinical and community settings, with the goal of improving prevention and treatment of diabetes in Native populations. The CAIANDTR Pilot & Feasibility Program is pleased to announce the availability of funding to support research consistent with this mission.

Pilot Grant Opportunity


The CAIANDTR Pilot & Feasibility Program provides support for early-stage investigators (ESIs) committed to conducting translational research related to diabetes in American Indian and Alaska Native (AI/AN) populations.

During this 18-month research and training program, funded investigators will:

  1. complete and publish a secondary analysis project relevant to diabetes in AI/ANs (Months 1-12) &
  2. develop a grant application seeking larger-scale funding for their research efforts (Months 13-18).

Successful applications will be those that hold promise of benefiting Native people, are scientifically meritorious, are feasible within the time and resources available, and represent an early step in an innovative line of inquiry that can continue beyond this initial investment. 

Application Materials

Application & Review Timeline

  • Call for Applications Opens:  July 5, 2022
  • Interest Form Due:  September 19, 2022
  • Complete Application Due:  October 3, 2022
  • Response from Reviewers:  October 24, 2022
  • Written Response to Review:  November 7, 2022
  • Notification of Award:  November 14, 2022
  • Project Period:  December 1, 2022 – May 31, 2024

Questions?

Contact Angela Brega, Pilot & Feasibility Program Director, at angela.brega@cuanschutz.edu for questions or to submit your interest form.

Current Pilot Project (2022-2023)


Liz Anderson Headshot
Liz Anderson, PhD, Assistant Professor, Western Carolina University

End-of-Life Care among American Indian and Alaska Native Medicare Enrollees with Diabetes

Despite high chronic disease and mortality rates, little is known about end-of-life care among American Indian and Alaska Native peoples (AIANs). AIANs have the highest diabetes rate of any racial or ethnic group. They are more likely to experience preventable hospitalizations and die from diabetes complications overall and at younger ages than non-Hispanic White adults. AIANs also have the highest premature mortality rate of any other race and are less likely to use hospice than Whites. Advance care planning (ACP) is a preventive intervention that allows people to express their medical wishes if they are unable to communicate and is associated with improved end-of-life care. Yet, research has found that 93% AIANs had never heard of a living will, a type of ACP. No study to date has examined hospitalization and hospice use at the end-of-life for a large nationally represented sample of AIANs. Thus, there is an urgent need to understand AIANs’ use of end-of-life health services. To address this gap, we will conduct secondary data analysis using Centers for Medicare and Medicaid Services 2019 Medicare data to understand end-of-life care with the following aims: 1) compare hospitalization and hospice use between AIAN and White beneficiaries by diabetes status; 2) examine associations between hospitalization and hospice use and personal characteristics between AIAN and White beneficiaries by diabetes status; and 3) conduct an exploratory analysis of ACP use in AIAN by patient characteristics to assess our ability to conduct a comprehensive multivariable analysis of ACP use in the future. 

Previously Funded Projects